肿瘤细胞治疗研究
英文原题：Cellular immunotherapies for central nervous system cancers.
过去 10 年间，细胞免疫疗法改变了血液系统恶性肿瘤患者的治疗选择。
过去十年，细胞免疫疗法改变了血液系统恶性肿瘤患者的治疗选择。有多种类型的细胞免疫疗法，各自可能用于中枢神经系统（CNS）癌症。本文综述脑和脊髓癌症的细胞治疗，重点介绍胶质母细胞瘤、弥漫性内生型脑桥胶质瘤/弥漫性中线胶质瘤、髓母细胞瘤及累及CNS的淋巴瘤临床前和临床研究。研究者已发现众多潜在治疗靶点，且若干早期临床试验证明了颅内肿瘤使用CAR-T和CAR-NK细胞的安全性和可行性。应对治疗失败机制，并在确保安全性的同时有效研究最有前景的疗法，将推动这些极具挑战性疾病的治疗进展。
Cellular Immunotherapies have transformed therapeutic options for individuals with hematologic malignancies over the past 10 years. There are several distinct types of cellular immunotherapies, each with potential applications to CNS cancers. Here, we review cancer cellular therapeutics for cancers of the brain and spinal cord, focusing on the preclinical and clinical studies that have been done in glioblastoma, diffuse intrinsic pontine glioma/diffuse midline glioma, medulloblastoma and lymphoma involving the central nervous system. Numerous potential therapeutic targets have been identified, and several early clinical trials have demonstrated safety and feasibility of administering CAR T and CAR NK cells for intracranial tumors. Addressing mechanisms of treatment failure, while safely and effectively studying the most promising therapies will advance the treatment landscape for these extremely challenging diseases.
MEMBER ACCOUNT
登录成功会直接打开下一页。
